Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer

Journal of Surgical Oncology

Volumn 63, Issue 3, 1996, Pages 201-208

  Colvett, Kyle T ^a   Althausen, Alex F ^a   Bassil, Barbara ^a   Heney, Niall M ^a   Mcgovern, Francis V ^a   Young II, Hugh H ^a   Kaufman, Donald S ^a   Zietman, Anthony L ^a   Shipley, William U ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

combined modality therapy; organ preservation; transurethral surgery

Indexed keywords

CISPLATIN; METHOTREXATE;

BLADDER CANCER; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CYSTECTOMY; HUMAN; ORGAN PRESERVATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; REVIEW; TRANSURETHRAL RESECTION;

BRACHYTHERAPY; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; NEOPLASM INVASIVENESS; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0029832042     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199611)63:3<201::AID-JSO13>3.0.CO;2-7     Document Type: Review

References (67)

1. Cancer Statistics, 1995. CA Cancer J. Clin 40:9-26, 1995.
2. Dunst J, Sauer R, Schrott KM, et al.: Organ-sparing treatment of advanced bladder cancer: A 10-year experience. Int J Radiat Oncol Biol Phys 30:261-266, 1994.
3. Housset M, Maulard C, Chretlen YC, et al.: Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study. J Clin Oncol 11:2150-2157, 1993.
4. Kaufman DS, Shipley WU, Griffin PP, et al.: Selective preservation by combination treatment of invasive bladder cancer. N Engl J Med 329:1377-1382, 1993.
5. Kachnic LA, Kaufman DS, Zietman AL, et al.: Selective bladder preservation by combined modality therapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 32(suppl 1):271, 1995 (abst).
6. Tester W, Porter A, Asbell S, et al.: Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25:783-790, 1993.
7. Tester W, Caplan R, Heaney J, et al.: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 88-02. J Clin Oncol 14:119-126, 1996.
8. Sweeney P, Kursh ED, Resnick MI: Partial cystectomy. Urol Clin North Am 19:10701-10711, 1992.
9. Resnick M, O'Conor V: Segmental resection for carcinoma of the bladder: Review of 102 patients. J Urol 109:1007, 1973.
10. Cummings K, Mason J, Correa R, et al.: Segmental resection in the management of bladder carcinoma. J Urol 119:56, 1978.
11. Magri J: Partial cystectomy: A review of 104 cases. Br J Urol 34:74, 1962.
12. Lindahl F, Jorgensen P, Equaad K: Partial cystectomy for transitional cell carcinoma of the bladder. Scand J Nephrol 18:125, 1984.
13. Kaneti J: Partial cystectomy in the management of bladder carcinoma. Eur Urol 12:249, 1986.
14. Barnes RW, Dick AL, Hadley HL, et al.: Survival following transurethral resection of bladder carcinoma. Cancer Res 37:2895-2898, 1977.
15. Herr HW: Conservative management of muscle-infiltrating bladder cancer: Prospective experience. J Urol 138:1162-1163, 1987.
16. Henry K, Miller J, Mori M, et al.: Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 140:964-967, 1988.
17. Solsona E, Iborra I, Ricos JV, et al.: Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder: Prospective study. J Urol 147:1513-1555, 1992.
18. Solsona E, Iborra I, Ricos JV, et al.: Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder: Prospective study after 5 years of minimum follow-up. Proc Soc Int Urol 1994 (abst 217).
19. Keating J, Zinke H, Morgan WR, et al.: Extended experience with neoadjuvant M-VAC chemotherapy for invasive transitional cell carcinoma of the urinary bladder. J Urol 141:244A, 1989.
20. Kurth K, Splinter TA, Jacqmin D, et al.: Transitional cell carcinoma of the bladder: A phase II study of chemotherapy in T3-4 NO MO of the EORTC GU group. In Alderson AR, Oliver RT, Hanham IW, Bloom HJ (eds): "Urological Oncology Dilemmas and Developments." New York: Wiley-Liss, 1991, p115-128.
21. Hall RR, Roberts JT: Neoadjuvant chemotherapy, a method to conserve the bladder? ECCO 6:1990 (abst 144).
22. Maffezzini M, Torelli T, Villa E, et al.: Systemic preoperative chemotherapy with cisplatin, methotrexate, and vinblastine for locally advanced bladder cancer: Local tumor response and early follow-up results. J Urol 145:741-743, 1991.
23. Roberts JT, Fossa SP, Richards SB, et al.: Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder. Br J Urol 68:162-168, 1991.
24. Farah R, Chodak GW, Vogelzgang NI, et al.: Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report). Int J Radiat Oncol Biol Phys 20:413-417, 1991.
25. Koiso K, Shipley W, Keuppens F, et al.: The status of bladder preserving therapeutic strategies in the management of patients with muscle invasive bladder cancer. Int J Urol 2(suppl 2):49-57, 1995.
26. Jahnson S, Pedersen J, Westman G: Bladder carcinoma - A 20 year review of radical irradiation therapy. Radiother Oncol 22:111-117, 1991.
27. Blandy J, England H, Evans SJW, et al.: T3 bladder cancer - The case for salvage cystectomy. Br J Urol 52:506-510, 1980.
28. Bloom HJG, Hendry W, Wallace DM, et al.: Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 54:136-151, 1982.
29. Gospadarowicz M, Hawkins N, Rawlings GA, et al.: Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis. J Urol 142:1448-1454, 1989.
30. Jenkins B, Caulfield M, Fowler CG, et al.: Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 62:343-346, 1988.
31. Mameghan H, Fisher R, Mameghan J, et al.: Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 31:247-254, 1995.
32. Quilty PM, Duncan W: Primary radical radiotherapy for T3 transitional cell cancer of the bladder: An analysis of survival and control. Int J Radiat Oncol Biol Phys 12:853-860, 1986.
33. 0 bladder cancer treated with radiotherapy. Br J Urol 55:386-391, 1983.
34. Shipley WU, Rose M: Bladder Cancer. The selection of patients for treatment by full-dose irradiation. Cancer 55:2278-2284, 1985.
35. De Neve W, Lybeert ML, Goor C, et al.: Radiotherapy for T2 and T3 carcinoma of the bladder: The influence of overall treatment time. Radiat Oncol 36:183-188, 1995.
36. Miller LS: Bladder cancer: Superiority of pre-operative radiation in cystectomy in clinical stage T3. Cancer 39:973-980, 1977.
37. Bloom HJG, Hendry WF, Wallace DM, Skeet RG: Treatment of T3 bladder cancer: Controlled trial of preoperative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 54:136-151, 1982.
38. Sell A, Jakobsen A, Nerstrom B: Treatment of advanced bladder cancer category T2, T3, T4a. Scand J Urol Nephrol 138(suppl): 193-201, 1991.
39. Horwich A, Pendlebury S, Dearnaley DP: Organ conservation in bladder cancer. Eur J Cancer 31(suppl 5):208, 1995.
40. Wallace D, Bloom HJG: The management of deeply infiltrating (T3) bladder carcinoma: Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (first report). Br J Urol 48:587-594, 1976.
41. Blackard DE, Byar DD, and the Veterans Administration Cooperative Urological Research Group: Results of a clinical trial of surgery and radiation in stages II and III carcinoma of the bladder. J Urol 108:875, 1972.
42. Cole D, Durrant K, Robert J, et al.: A pilot study of accelerated fractionation in the radiotherapy of invasive carcinoma of the bladder. Br J Radiol 65:792-798, 1992.
43. Naslund I, Nilsson B, Littbrand B: Hyper-fractionated radiotherapy of bladder cancer: A 10 year follow up of a randomized clinical trial. Acta Oncol 33:397-402, 1994.
44. Van der Werf-Messing B, Menon RS, Hop WCJ: Cancer of the urinary bladder category T2, T3 treated by interstitial radium implant: Second report, Int J Radiat Oncol Biol Phys 9:481-485, 1993.
45. Wijnmalen A, Van der Werf-Messing BHP: Factors influencing the prognosis in bladder cancer. Int J Radiat Oncol Biol Phys 12:559-565, 1986.
46. Rozan R, Albuisson E, Donnarieix D, et al.: Interstitial iridium-192 for bladder cancer (a multicentric survey of 205 patients). Int J Radiat Oncol Biol Phys 24:469-477, 1992.
47. Monnen LM, Horenblas S, Van der Voet JC, et al.: Bladder conservation in selected T1G3 and muscle-invasive T2-T3a bladder carcinoma using combination therapy of surgery and iridium-192 implantation. Br J Urol 74:322-327, 1994.
48. Mommsen S, Jakobsen A, Sell A: Quality of life in patients with advanced bladder cancer. Scand J Urol Nephrol 145(suppl):743, 1989.
49. Lynch WJ, Jenkins BJ, Fowler CG: The quality of life after radical radiotherapy for bladder cancer. Br J Urol 70:519-521, 1992.
50. Scher H, Herr H, Sternberg C, et al.: MVAC (methotrexate, vinblastine, Adriamycin, and cisplatin) and bladder preservation. In Splinter T, Scher HI (eds): "Neoadjuvant Chemotherapy of Invasive Bladder Cancer." New York: Alan R Liss, 1990, p179-186.
51. Sternberg C, Pansadoro V, Lauretti S, et al.: Neo-adjuvant M-VAC (methotrexate, vinblastine, Adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle infiltrating transitional cell carcinoma of the bladder. Urol Oncol Clin (in press).
52. Sternberg C, Arena M, Calabresi F, et al.: Neo-adjuvant M-VAC (methotrexate, vinblastine, Adriamycin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer 72:1975-1982, 1993.
53. Herr HE, Scher HI: Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 12:975-980, 1994.
54. Soquet Y: Combined surgery and adjuvant chemotherapy with high-dose methotrexate and folinic acid rescue (HDMTX-CF) for infiltrating tumors of the bladder. Br J Urol 53:439-443, 1981.
55. Simon SD, Srougi M: Neo-adjuvant M-VAC chemotherapy and partial cystectomy for treatment of locally invasive transitional cell carcinoma of the bladder. In Splinter T, Scher HI (eds): "Neoadjuvant Chemotherapy of Invasive Bladder Cancer." New York: Alan R Liss, 1990, p169-173.
56. Amiel J, Quintens H, Thyss A, et al.: Combination transurethral resection and systemic chemotherapy as primary treatment of infiltrating bladder tumors (pT2-pT4 Nx MO). J Urol 94:333-336, 1988.
57. Srougi M, Simon SD: Primary methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: A 5-year follow-up. J Urol 151:593-597, 1994.
58. Hunis A, Levin M, Turek A: Modified M-VAC as neo-adjuvant chemotherapy (NCH) in bladder cancer (BC), the one year later report. Am Soc Clin Oncol 11:A636, 1992 (abst).
59. Martinez-Piniero JA, Jiminez-Leon J, Martinez-Piniero L: Aggressive transurethral resection combined with systemic chemotherapy for locally invasive TCC of the urinary bladder. Soc Int Urol 1991:226 (abst 216).
60. Pas-Ares L, Lianes P, Diaz-Puente M, et al.: Neoadjuvant chemotherapy (CT) aiming at bladder preservation. In Third International Congress on Neoadjuvant Chemotherapy, Paris 34, 1991 (abst).
61. Durand R, Vanderbyl S: Response of cell populations in spheroids to radiation-drug combinations. Natl Cancer Inst Monog 6:95-100, 1988.
62. Begg A: Cisplatin and radiation: Interaction probabilities and other therapeutic possibilities. Int J Radiat Oncol Biol Phys 19:1183-1189, 1990.
63. Flentje M, Eble M, Haner U: Additive effects of cisplatin and radiation in human tumor cells under toxic conditions. Radiother Oncol 24:60-63, 1991.
64. Fung CY, Shipley WU, Kaufman D, et al.: Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol 9:1533-1542, 1991.
65. Martinez-Piniero JA, Martin MG, Arocena NF, et al.: Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol 153:964-973, 1995.
66. Given RW, Parsons JT, McCarley D, Wajsman Z. Bladder-sparing multimodality treatment of muscle-invading bladder cancer: A five-year follow-up. Urology 46:499-505, 1995.
67. Kachnic LA, Shipley WU, Griffin PP, et al.: Combined modality treatment with selective bladder conservation for invasive bladder cancer: Long-term tolerance in the female patient. Cancer (in press), 1996.